Abstract

BackgroundDuchenne muscular dystrophy (DMD) is a severe neuromuscular disease that affects 1 in 3500 boys. The disease is characterized by progressive muscle degeneration that results from mutations in or loss of the cytoskeletal protein, dystrophin, from the glycoprotein membrane complex, thus increasing the susceptibility of contractile muscle to injury. To date, disease progression is typically assessed using invasive techniques such as muscle biopsies, and while there are recent reports of the use of magnetic resonance, ultrasound and optical imaging technologies to address the issue of disease progression and monitoring therapeutic intervention in dystrophic mice, our study aims to validate the use of imaging biomarkers (muscle perfusion and metabolism) in a longitudinal assessment of skeletal muscle degeneration/regeneration in two murine models of muscular dystrophy.MethodsWild-type (w.t.) and dystrophic mice (weakly-affected mdx mice that are characterized by a point mutation in dystrophin; severely-affected mdx:utrn-/- (udx) mice that lack functional dystrophin and are null for utrophin) were exercised three times a week for 30 minutes. To follow the progression of DMD, accumulation of 18 F-FDG, a measure of glucose metabolism, in both wild-type and affected mice was measured with a small animal PET scanner (GE eXplore Vista). To assess changes in blood flow and blood volume in the hind limb skeletal muscle, mice were injected intravenously with a CT contrast agent, and imaged with a small animal CT scanner (GE eXplore Ultra).ResultsIn hind limb skeletal muscle of both weakly-affected mdx mice and in severely-affected udx mice, we demonstrate an early, transient increase in both 18F-FDG uptake, and in blood flow and blood volume. Histological analysis of H&E-stained tissue collected from parallel littermates demonstrates the presence of both inflammatory infiltrate and centrally-located nuclei, a classic hallmark of myofibrillar regeneration. In both groups of affected mice, the early transient response was succeeded by a progressive decline in muscle perfusion and metabolism; this was also evidenced histologically.ConclusionsThe present study demonstrates the utility of non-invasive imaging biomarkers in characterizing muscle degeneration/regeneration in murine models of DMD. These techniques may now provide a promising alternative for assessing both disease progression and the efficacy of new therapeutic treatments in patients.

Highlights

  • Duchenne muscular dystrophy (DMD) is a severe neuromuscular disease that affects 1 in 3500 boys

  • While a diagnosis of DMD is usually made in patients approximately 5 years of age by assessment of family history and PCR genotyping [12], analysis of disease progression typically relies upon the measurement of muscle strength [13], creatine kinase levels [14] and painful, invasive muscle biopsies [15]

  • In the present study, we demonstrate the utility of dynamic contrast enhanced computed tomography (DCE-CT) and Positron emission tomography (PET) scanning to, firstly, longitudinally assess changes in muscle perfusion and metabolism as disease progresses in two murine models of DMD, and to, secondly, provide a baseline for monitoring the success of various therapeutics

Read more

Summary

Introduction

Duchenne muscular dystrophy (DMD) is a severe neuromuscular disease that affects 1 in 3500 boys. Disease progression is typically assessed using invasive techniques such as muscle biopsies, and while there are recent reports of the use of magnetic resonance, ultrasound and optical imaging technologies to address the issue of disease progression and monitoring therapeutic intervention in dystrophic mice, our study aims to validate the use of imaging biomarkers (muscle perfusion and metabolism) in a longitudinal assessment of skeletal muscle degeneration/regeneration in two murine models of muscular dystrophy. The disease is characterized by progressive skeletal muscle degeneration that arises due (nNOS) that is normally localized to the sarcolemma as part of the DGC [5,6,7] This DGC protein plays a role in myofiber differentiation [8], modulation of contractile force [9], and exercise-induced glucose uptake [10]. In the present study, we demonstrate the utility of dynamic contrast enhanced computed tomography (DCE-CT) and PET scanning to, firstly, longitudinally assess changes in muscle perfusion and metabolism as disease progresses in two murine models of DMD, and to, secondly, provide a baseline for monitoring the success (or failure) of various therapeutics

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call